Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

benzinga.com/25/05/45674452/intellia-therapeutics-rare-heart-disease-candidate-reports-liver-enzyme-spike-in-phase-3-trial-but-stays-on-cours

Intellia Therapeutics Inc (NASDAQ: NTLA) said on Wednesday that a single, recent, asymptomatic patient has had grade 4 (severe) liver transaminase elevations (liver enzymes) based on laboratory tests in its Phase 3 MAGNITUDE study.
The trial is evaluating nexiguran ziclumeran (nex-z,…

This story appeared on benzinga.com, 2025-05-29 15:25:36.
The Entire Business World on a Single Page. Free to Use →